Amyloid clinical trials
30 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones look like a fit.
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
- Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
- Stem Cell Therapy for Early Alzheimer's Disease
- Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
- Innate Immunity Stimulation Via TLR9 in Early AD
- A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
- Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms
- A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
- Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzheimer's Disease
- A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
- Brain NAD in Alzheimer's Disease
- Cognitive Neurology Unit Clinical Registry
- Alzheimer's Tau Platform: Master Protocol
- Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
- Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
- Gamma-Music Based Intervention for Mild Alzheimer's Disease
- Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
- 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
- Alzheimer's Tau Platform: Regimen A - AADvac1
- Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
- BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers
- TMS Pilot in Early AD II
- Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
- Tau PET Outcomes With Anti-amyloid Immunotherapies
- Rapamycin - Effects on Alzheimer's and Cognitive Health
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “Amyloid” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.